Cipla: Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Read full article »
Cipla develops and produces drugs for the treatment of arthritis, diabetes, weight control, depression and cardiovascular diseases.
Read more